Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
NCT02415621Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2015
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Moffitt Cancer Center. Primary endpoint: Prostatic Specific Antigen Response Rate at 2 months. Started Apr 2015; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02415621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415621.